Navigation Links
Pharsight Signs New Diabetes Meta-Database Customer
Date:3/27/2008

Top 20 Global Pharmaceutical Company Licenses Public-Source Database to Quantify Competitive Treatment Landscape and Support Model-Based Drug

Development

MOUNTAIN VIEW, Calif., March 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it has licensed its public-source Type II Diabetes meta- database to a Top 20 global pharmaceutical company. The customer expects to use the database to build quantitative models of the competitive landscape for oral diabetes treatments that will support clinical program decision-making for promising compounds in its diabetes pipeline. This is the second license Pharsight has sold for its diabetes meta-database.

Pharsight's meta-database for Type II Non-Insulin Dependent Diabetes Mellitus (NIDDM) captures clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments and more than 30 clinical endpoints.

Pharsight has assembled a team of clinical database and clinical pharmacy experts dedicated to extracting information from the public domain and transforming this information into model-ready datasets. These datasets are used by biopharmaceutical companies and Pharsight scientific consultants to answer a variety of drug development questions. Pharsight offers public-source meta-databases in nine therapeutic areas, covering 20 disease indications. Additional information is available at http://www.pharsight.com/services/scs_sub_metadata.php.

"Pharsight is pleased that another leading pharmaceutical company has elected to use our meta-database to enable objective comparisons of drug effects for its diabetes programs," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Using public domain data extracted from the scientific literature to build predictive models of the competitive landscape provides a quantitative means for understanding the clinical potential of a drug candidate and earlier assessment of its' competitive viability. Pharsight systematically compiles public-source clinical databases, many in high-prevalence disease areas, with a deliberate focus to enable knowledge sharing and efficient drug-disease modeling to support our client's critical drug development decisions."

About Pharsight Public-Source Meta-databases

Pharsight meta-databases provide highly structured quantitative information from the public-source scientific literature that can be used to understand the competitive landscape for a particular therapeutic area and indication. Meta-databases provide a starting point for model-based drug development approaches, and when combined with proprietary data on specific compound(s) can be used to manage risk and address specific drug development program questions concerning dose selection, efficient and effective trial design, and "go/no-go" decisions. Pharsight offers meta-databases in nine therapeutic areas, covering 20 disease indications that include type II diabetes, thrombosis, depression and insomnia.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the design and performance of the Pharsight public-source meta-database offering are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on February 14, 2008. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight to Present at eClinical Forum
2. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
3. FDA and Pharsight Continue to Collaborate Under CRADA
4. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
5. Pharsight Achieves $7.3 Million in Quarterly Revenue
6. Pharsight Expands Global Consulting Services Teams
7. Pharsight to Host European Software Conference
8. Pharsight Files Application for Nasdaq Capital Market Listing
9. Governor Strickland Signs House Bill 125 Into Law
10. Know Suicides Warning Signs
11. Godfather of Physical Fitness, Jack LaLanne, Signs Newest Book at Borders Penn Plaza Friday, March 21st from 5:30 PM to 7:30 PM ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... , ... A recent report indicates that circa 79 percent of 483 warning ... data integrity. The FDA outlines their expectations for quality critical instrumentation in the GMP ... the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, this webinar ...
(Date:8/16/2017)... ... ... The next Patient Care Academy at Kalamazoo Valley Community College begins September ... seven-week long Patient Care Academy are eligible to take the State of Michigan examination ... in Kalamazoo is $24,428.* , As a CNA, one is equipped for employment in ...
(Date:8/16/2017)... ... 2017 , ... Greenfield Advisors is honored to be named to Inc. Magazine’s ... in a row. The Inc. 5000 list honors private businesses across the country that ... list once is a great accomplishment, but for us to be included again goes ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test Now® ... ranked #4429 on the newly released, 36th annual Inc. 5000 , the most ... at the most successful companies within the American economy’s most dynamic segment — its ...
(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology: